loading

Why is Aptose Biosciences Inc (APTO) Stock down?

We've noticed a 5.90% decline in Aptose Biosciences Inc (APTO) stock during the 2024-06-14 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
10 Nov, 2023:

Shares of Aptose Biosciences Inc (APTO) dropped by 24.38% from $3.24 to $2.45 in the trading on Friday, November 10, 2023. The reason why APTO is down today is due to the company's Q3 financial results. Aptose Biosciences reported a loss of $11.4 million, equivalent to $1.76 per share, which exceeded Wall Street expectations. Analysts had anticipated a loss of $2.16 per share. The stock, which traded at $9.75 a year ago, closed at $3.09 in the final minutes of Thursday's trading session.

30 Oct, 2023:

Shares of Aptose Biosciences Inc (APTO) dropped by 13.52% from $3.18 to $2.75 in the trading on Monday, October 30, 2023. The reason why APTO is down today is due to the release of clinical updates related to Aptose's lead compound tuspetinib (TUS) at the European School of Haematology (ESH) 6th International Conference. Tuspetinib is a precision targeted kinase inhibitor designed for the treatment of acute myeloid leukemia (AML). Key highlights from the update include:

  • More than 140 patients have been treated with tuspetinib.
  • Favorable safety profiles observed, with no TUS-related adverse events of QTc prolongation, differentiation syndrome, or dose-limiting toxicities.
  • Tuspetinib showed high activity as a single agent, delivering positive response rates.
  • The combination of tuspetinib with venetoclax (VEN) demonstrated promising overall response rates, particularly in patients who had previously failed venetoclax treatment. These clinical findings indicate the potential of tuspetinib in treating difficult-to-treat AML patient populations, including those who have failed venetoclax treatment. The positive safety and efficacy data suggest a path for accelerated approval for certain patient groups.
$83.51
price down icon 0.88%
$26.25
price down icon 0.49%
$161.10
price down icon 3.28%
$160.50
price up icon 0.21%
$92.58
price down icon 3.51%
$385.35
price down icon 0.78%
Cap:     |  Volume (24h):